FDA Announces It Will Investigate Reported Increased Risk of Clotting from Yasmin and Yaz

The U.S. Food and Drug Administration (FDA) announced today that it will investigate and evaluate the risk of blood clots in women who use birth control pill containing drospirenone, such as Yasmin and Yaz. (5/31/11 FDA Public Announcement)

This is an important step as published studies have reported a greater risk of blood clots for women taking birth control pills containing drospirenone as compared to the risk in women taking birth control pills containing another progestin known as levonorgestrel.

The European Medicines Agency (EMA) announced on May 27, 2011, that it is updating the product information on oral contraceptives containing drospirenone and ethinyl estradiol regarding the risk of venous thromboembolism after review of all available data, including the same newly published data FDA is reviewing.

For more information on the dangers of Yasmin and Yaz, visit our Yasmin/Yaz Webpage and Video.